Circulating miRNAs in extracellular vesicles related to treatment response in patients with idiopathic membranous nephropathy

被引:10
|
作者
Sun, In O. [1 ]
Bae, Yun-Ui [2 ]
Lee, Haekyung [3 ]
Kim, Hyoungnae [3 ]
Jeon, Jin Seok [3 ]
Noh, Hyunjin [3 ]
Choi, Jong-Soo [4 ]
Doh, Kyung-Oh [4 ]
Kwon, Soon Hyo [3 ]
机构
[1] Presbyterian Med Ctr, Dept Internal Med, Div Nephrol, Jeonju, South Korea
[2] Keimyung Univ, Sch Med, Dongsan Hosp, Dept Internal Med, Daegu, South Korea
[3] Soonchunhyang Univ, Seoul Hosp, Div Nephrol, 59 Daesagwan Ro, Seoul 04401, South Korea
[4] Yeungnam Univ, Coll Med, Dept Physiol, Daegu 42415, South Korea
基金
新加坡国家研究基金会;
关键词
Extracellular vesicles; microRNAs; Glomerulonephritis; Treatment outcome; URINARY TRANSFORMING GROWTH-FACTOR-BETA-1; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; A(2) RECEPTOR ANTIBODIES; NEPHROTIC SYNDROME; PERMEABILITY FACTORS; PHOSPHOLIPASE-A2; RECEPTOR; DIFFERENTIAL EXPRESSION; TGF-BETA; AUTOANTIBODIES; SERUM;
D O I
10.1186/s12967-022-03430-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Extracellular vesicle (EV)-microRNAs (miRNAs) are potential biomarkers for various renal diseases. This study attempted to identify the circulating EV-miRNA signature not only for discriminating idiopathic membranous nephropathy (IMN) from idiopathic nephrotic syndrome (INS), but also to predict the treatment response of patients with IMN. Methods We prospectively enrolled 60 participants, including those with IMN (n = 19) and INS (n = 21) and healthy volunteers (HVs; n = 20) in this study. Using RNA sequencing, we assessed the serum EV-miRNA profiles of all participants. To identify the EV-miRNAs predictive of treatment response in IMN, we also analyzed EV-miRNAs among patients with IMN with and without clinical remission. Results The expression levels of 3 miRNAs differed between IMN patients, INS patients and HVs. In addition, compared to HVs, RNA sequencing revealed differential expression of 77 and 44 EV-miRNAs in patients with IMN without and with remission, respectively. We also identified statistically significant (|fold change >= 2, p < 0.05) differences in the expression levels of 23 miRNAs in IMN without remission. Biological pathway analysis of miRNAs in IMN without remission indicated that they are likely involved in various pathways, including renal fibrosis. Conclusion Our study identified EV-miRNAs associated with IMN as well as those associations with therapeutic response. Therefore, these circulating EV-miRNAs may be used as potential markers for the diagnosis and prediction of treatment response in patients with IMN.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Circulating miRNAs in extracellular vesicles related to treatment response in patients with idiopathic membranous nephropathy
    In O. Sun
    Yun-Ui Bae
    Haekyung Lee
    Hyoungnae Kim
    Jin Seok Jeon
    Hyunjin Noh
    Jong-Soo Choi
    Kyung-Oh Doh
    Soon Hyo Kwon
    Journal of Translational Medicine, 20
  • [2] Treatment with rituximab in idiopathic membranous nephropathy
    Fiorentino, Marco
    Tondolo, Francesco
    Bruno, Francesca
    Infante, Barbara
    Grandaliano, Giuseppe
    Gesualdo, Loreto
    Manno, Carlo
    CLINICAL KIDNEY JOURNAL, 2016, 9 (06) : 788 - 793
  • [3] Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy
    Li, Ping
    Wei, Ri-bao
    Tang, Li
    Wu, Jie
    Zhang, Xue-guang
    Chen, Xiang-mei
    CLINICAL NEPHROLOGY, 2012, 78 (06) : 456 - 464
  • [4] Treatment of idiopathic membranous nephropathy
    Hofstra, Julia M.
    Fervenza, Fernando C.
    Wetzels, Jack F. M.
    NATURE REVIEWS NEPHROLOGY, 2013, 9 (08) : 443 - 458
  • [5] Treatment of Idiopathic Membranous Nephropathy
    Waldman, Meryl
    Austin, Howard A., III
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2012, 23 (10): : 1617 - 1630
  • [6] Small RNA sequencing of extracellular vesicles identifies circulating miRNAs related to inflammation and oxidative stress in HIV patients
    Chettimada, Sukrutha
    Lorenz, David R.
    Misra, Vikas
    Wolinsky, Steven M.
    Gabuzda, Dana
    BMC IMMUNOLOGY, 2020, 21 (01)
  • [7] Treatment pattern in patients with idiopathic membranous nephropathy-practices in Sweden at the start of the millennium
    Lonnbro-Widgren, Jennie
    Molne, Johan
    Haraldsson, Borje
    Nystrom, Jenny
    CLINICAL KIDNEY JOURNAL, 2016, 9 (02) : 227 - 233
  • [8] Clinical outcomes and effects of treatment in older patients with idiopathic membranous nephropathy
    Kim, Yaeni
    Yoon, Hye Eun
    Chung, Byung Ha
    Choi, Bum Soon
    Park, Cheol Whee
    Yang, Chul Woo
    Kim, Yong-Soo
    Hong, Yu Ah
    Kim, Suk Young
    Chang, Yoon-Kyung
    Hwang, Hyeon Seok
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 1091 - 1099
  • [9] Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy
    Li, Shu
    Wang, Ling
    Zhang, Minfang
    Zhou, Wenyan
    Fang, Wei
    Wang, Qin
    Qi, Chaojun
    Mou, Shan
    Shao, Xinghua
    Ni, Zhaohui
    NEPHRON, 2017, 135 (02) : 87 - 96
  • [10] Rituximab treatment of idiopathic membranous nephropathy
    Fervenza, F. C.
    Cosio, F. G.
    Erickson, S. B.
    Specks, U.
    Herzenberg, A. M.
    Dillon, J. J.
    Leung, N.
    Cohen, I. M.
    Wochos, D. N.
    Bergstralh, E.
    Hladunewich, M.
    Cattran, D. C.
    KIDNEY INTERNATIONAL, 2008, 73 (01) : 117 - 125